STOCK TITAN

Tango Therapeutics Inc - TNGX STOCK NEWS

Welcome to our dedicated news page for Tango Therapeutics (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tango Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tango Therapeutics's position in the market.

Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) will have its President and CEO, Barbara Weber, M.D., present at the Jefferies London Healthcare Conference on November 14, 2023, at 1:00 PM GMT. The presentation will be available via live webcast and will be archived on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences
-
Rhea-AI Summary
Tango Therapeutics announces five abstracts selected for poster presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
-
Rhea-AI Summary
Tango Therapeutics receives FDA clearance for IND application of TNG348, a novel inhibitor of USP1, for the treatment of BRCA1/2 mutant and other HRD+ cancers. Clinical trial to begin in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
Rhea-AI Summary
Tango Therapeutics CEO to participate in H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences
-
Rhea-AI Summary
Tango Therapeutics announces changes to its Board of Directors. John Ketchum appointed, Aaron Davis steps down. Ketchum's global commercial experience in oncology will be valuable for the company. No concrete positive or negative business takes affecting stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
management
-
Rhea-AI Summary
Tango Therapeutics to sell 15.5M shares of Common Stock at $5.15 per share in a private investment, expecting $80M gross proceeds. The funding will strengthen balance sheet and support ongoing clinical programs. Nextech leads financing with participation from other investors. Proceeds to enable rapid expansion and fund operations into 2026. Securities sold in PIPE not registered under Securities Act of 1933.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.26%
Tags
none
Rhea-AI Summary
Tango Therapeutics reports Q2 2023 financial results and business highlights. First patient dosed in phase 1/2 trials of TNG462, TNG908, and TNG260. Alan Huang to step down as CSO, Jannik Andersen to be appointed as successor. $310.7 million in cash. Collaboration revenue increased to $9.6 million. License revenue of $5.0 million. R&D expenses increased to $28.7 million. Net loss of $20.7 million for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
-
Rhea-AI Summary
Tango Therapeutics announced the initiation of a phase 1/2 clinical trial for TNG260, a first-in-class inhibitor of the CoREST complex, in combination with pembrolizumab for patients with STK11-mutant cancers. This trial aims to reverse immune evasion caused by STK11 loss-of-function mutations, which contribute to resistance to immunotherapy. STK11 mutations occur in various cancers, and TNG260 has shown promising results in preclinical studies. The FDA granted Fast Track designation for TNG260 in combination with an anti-PD-1 antibody for advanced non-small cell lung cancer with STK11-mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences
Tango Therapeutics Inc

Nasdaq:TNGX

TNGX Rankings

TNGX Stock Data

785.44M
46.25M
13.51%
88.51%
9.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About TNGX

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util